

# Vojtech Novotn

## List of Publications by Citations

Source: <https://exaly.com/author-pdf/8866857/vojtech-novotny-publications-by-citations.pdf>

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

5  
papers

2,532  
citations

4  
h-index

5  
g-index

5  
ext. papers

3,468  
ext. citations

33.1  
avg, IF

3.89  
L-index

#	Paper	IF	Citations
5	Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , 2018, 379, 2097-2107	59.2	1277
4	Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2017, 377, 1319-1330	59.2	1122
3	Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 618-628	18.1	120
2	Heart failure is the strongest predictor of acute kidney injury in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction. <i>Kardiologia Polska</i> , 2016, 74, 18-24	0.9	13
1	State-of-the-art PCI for coronary artery chronic total occlusion. <i>Intervencní A Akutní Kardiologie</i> , 2020, 19, 31-38	0	0